OncoMatch/Clinical Trials/NCT07450976
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Is NCT07450976 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies SHR-A1904 for for biliary tract cancer.
Treatment: SHR-A1904 for — This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: CLDN18 positive expression
CLDN18.2 positive expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic chemotherapy
Subjects who failed or intolerance after systemic chemotherapies
Cannot have received: anti-tumor treatment (chemotherapy, radiotherapy, immunotherapy, biotherapy, or other clinical research drugs)
Received anti-tumor treatment such as chemotherapy, radiotherapy, immunotherapy, biotherapy or other clinical research drugs within 4 weeks before the first administration
Lab requirements
Liver function
Child-Pugh liver function grade C excluded
Cardiac function
Severe heart disease within 6 months before first administration excluded
The main organ function is normal, in line with the program requirements; Child-Pugh liver function grade C excluded; severe heart disease within 6 months before first administration excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify